Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic
  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Its Clinical Pipeline

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the reexpression of the NPRL2 gene. “The collaborators conducted the studies using the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 gene to KRAS/STK11 mutant, anti-PD1 resistant, human NSCLC metastases in humanized mouse models, presenting the data at the 2023 American Association of Cancer Research (‘AACR’) annual meeting, held in April,” reads a recent article. “According to Genprex President, Chairman and CEO Rodney Varner, the use of ONCOPREX(R) to deliver the NPRL2 tumor suppressor gene ‘positions Genprex to expand our clinical pipeline with a new drug candidate’ and gives the company ‘further confidence in the potentially broad-based application of our non-viral delivery system, which may provide a multitude of potential pipeline opportunities in the future.’”

To view the full article, visit https://ibn.fm/wXdUI

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing treatments for patients living with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company was founded in 2009 and is headquartered in Austin, Texas. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.